



(51) International Patent Classification:

C07D 213/56 (2006.01) **C07D 401/14** (2006.01)
C07D 237/08 (2006.01) **C07D 403/12** (2006.01)
C07D 279/12 (2006.01) **A61K 31/44** (2006.01)
C07D 401/12 (2006.01) **A61P 35/00** (2006.01)

(21) International Application Number:

PCT/US2011/042215

(22) International Filing Date:

28 June 2011 (28.06.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/359,569 29 June 2010 (29.06.2010) US

(71) **Applicants** (for all designated States except US): **IRM LLC** [US/US]; 131 Front Street, P.O. Box HM 2899, Hamilton, HM LX (BM). **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) **Inventors/Applicants** (for US only): **CHENG, Dai** [US/US]; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **ZHANG, Guobao** [US/US]; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121 (US). **HAN, Dong** [CN/US]; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **GAO, Wenqi** [CN/US]; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **PAN, Shifeng** [US/US]; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **SHEN, Lichun** [CN/US]; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936 (US). **LELETI, Rajender Reddy** [IN/

US]; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936 (US).

(74) **Agents**: **TONGCO WU, Emily** et al.; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).



Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) **Title**: COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY



(57) **Abstract**: The present invention relates to compositions and methods for modulating the Wnt signaling pathway, using compounds having Formula (1) and (3); wherein A, B, Y and Z all represent rings, and R¹, R², R³ are as defined herein.